Sunday, February 23, 2025 | 12:40 AM ISTहिंदी में पढें
Business Standard
Notification Icon
userprofile IconSearch

Aurobindo Pharma dips 5% on weak operational performance in June quarter

Aurobindo Pharma has entered into definitive agreements under which the Company will subscribe to fresh equity shares in Cronus amounting to Rs 420 crore

Aurobindo Pharma
Premium

Aurobindo Pharma

SI Reporter Mumbai
Shares of Aurobindo Pharma dipped 5 per cent at Rs 781 on the BSE in the intra-day trade on Friday after the company reported a disappointing operational performance in June 2021 quarter (Q1FY22), amid decline across US market & antiretroviral (ARVs).

In Q1FY22, the company’s profit after tax (PAT) was down 1.7 per cent year on year (YoY) and 4 per cent quarter on quarter (QoQ) at Rs 770 crore. It was, however, in-line with analysts' estimate on higher than expected other income and a lower tax rate. Revenue, meanwhile, de-grew 3.8 per cent YoY and 5.0 per cent

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in